Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti–PD-1 Therapy in NRAS-Mutant Melanoma

Journal of Investigative Dermatology(2025)10.1016/j.jid.2025.03.021Source: DataRank Database

Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti–PD-1 Therapy in NRAS-Mutant Melanoma is a research paper published in Journal of Investigative Dermatology (2025). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

Linked data & code

uniprot doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 3.57)OA: greenTopics (62)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Dinghao Wang ORCID,Timothy J. Purwin ORCID,Sophia Ran ORCID,Qi Yang ORCID,Qingrun Zhang ORCID

Live enrichment

PubMed:40204067 PMC:PMC12354106 OpenAlex:https://openalex.org/W4409299954

NSERC

Grant: RTI-2021-00675

NSERC

Grant: RGPIN-2018-05147

NIH

Grant: RF1AG078459

Natural Sciences and Engineering Research Council of Canada

Grant: unidentified

unidentified

Southern Illinois University School of Medicine

Alberta Innovates

FWCI

3.57

Citation Percentile

0.9%

Citation Trend

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12354106/

publisherhttps://api.elsevier.com/content/article/PII:S0022202X25003847?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0022202X25003847?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jid.2025.03.021

Fields of Study

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitorsinterferon and immune responses03 medical and health sciences0302 clinical medicine

MeSH Terms

Ubiquitin-Specific Peptidase 7Immune Checkpoint InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsDrug SynergismHumansMelanomaMembrane ProteinsMutationSkin NeoplasmsGTP PhosphohydrolasesMonomeric GTP-Binding ProteinsMAP Kinase Signaling SystemXenograft Model Antitumor AssaysCell Line, TumorProtein Kinase InhibitorsMAP Kinase Kinase 1MAP Kinase Kinase 2Cell ProliferationMiceProgrammed Cell Death 1 Receptor

Keywords

MelanomaNeuroblastoma RAS viral oncogene homologCancer researchMutantImmune systemMedicineChemistryImmunologyCancerInternal medicineKRASMEKPD-1Cutaneous MelanomaNrasUsp7Skin NeoplasmsMAP Kinase Signaling SystemProgrammed Cell Death 1 ReceptorMAP Kinase Kinase 2MAP Kinase Kinase 1Membrane ProteinsDrug SynergismXenograft Model Antitumor AssaysArticleGTP PhosphohydrolasesUbiquitin-Specific Peptidase 7MiceCell Line, TumorMutationAntineoplastic Combined Chemotherapy ProtocolsAnimalsHumansImmune Checkpoint InhibitorsProtein Kinase InhibitorsCell Proliferation

Sustainable Development Goals

SDG 0: Zero hunger